IASLC TTLC 2024 | Osimertinib and chemotherapy in EGFR+ lung cancer with TP53 and RB1 alterations

Monica Chen, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses results from a study assessing first-line osimertinib, platinum, and etoposide in patients with metastatic EGFR-mutant lung cancer with TP53 and RB1 alterations. A total of 11 patients with varying histologies were enrolled and the rate of transformation to small cell lung cancer was not significantly different. Dr Chen additionally highlights the next steps for this study, which include cell subtyping to further elucidate the biological processes behind disease transformation. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.